首页 > 最新文献

Urologia Journal最新文献

英文 中文
Quantitative analysis of dynamic-contrast MRI for the assessment of prostate cancer in the transition zone. 动态磁共振造影定量分析前列腺癌过渡区。
IF 0.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-26 DOI: 10.1177/03915603251414596
Mariko Doai, Tamaki Kondo, Yuka Nishino, Ippei Chikazawa, Sohsuke Yamada, Keiya Hirata, Katsuhito Miyazawa

Purpose: Differentiating prostate cancer (PCa) in the transition zone (TZ) from benign prostate hyperplasia based on MRI findings has often been challenging. This study aims to evaluate the utility of a quantitative analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using time-resolved angiography with stochastic trajectories‒volumetric interpolated breath-hold examination (TWIST-VIBE) in cases of PCa in the TZ.

Methods: In this retrospective study, we examined the biopsy findings of 23 patients with elevated prostate-specific antigen (PSA) levels (>4 ng/mL) who underwent DCE-MRI using TWIST-VIBE. The parameters analyzed included Ktrans (the transfer constant), Kep (the reflux constant), Ve (the extravascular extracellular volume fraction), and the initial area under the curve on the Tissue 4D platform (Siemens).

Results: The quantitative analysis revealed no significant differences in any of the examined parameters between positive and negative PCa in the TZ. Additionally, there were no significant differences among the histological grades of PCa in the TZ.

Conclusion: A quantitative analysis of findings obtained by DCE-MRI using TWIST-VIBE did not yield statistically significant results for differentiating the status of PCa in the TZ. However, DCE-MRI using TWIST-VIBE, an ultrafast DCE-MRI technique, may be useful for evaluating tumor hemodynamics and assessing the size dependence of prostate cancer lesions in the transition zone.

目的:根据MRI表现区分过渡区前列腺癌(PCa)与良性前列腺增生一直具有挑战性。本研究旨在评估动态对比增强磁共振成像(DCE-MRI)定量分析的效用,该定量分析使用时间分辨血管造影与随机轨迹-体积内插屏气检查(TWIST-VIBE)在TZ的PCa病例中。方法:在这项回顾性研究中,我们检查了23例前列腺特异性抗原(PSA)水平升高(>4 ng/mL)的患者,并使用TWIST-VIBE进行了DCE-MRI检查。分析的参数包括Ktrans(传递常数)、Kep(回流常数)、Ve(血管外细胞外体积分数)和Tissue 4D平台(Siemens)曲线下的初始面积。结果:定量分析显示,在TZ中阳性和阴性PCa之间,任何检查参数均无显著差异。此外,在TZ中,前列腺癌的组织学分级没有显著差异。结论:使用TWIST-VIBE对DCE-MRI所获得的结果进行定量分析,对于鉴别TZ中PCa的状态没有统计学意义。然而,使用TWIST-VIBE(一种超快速DCE-MRI技术)的DCE-MRI可能有助于评估肿瘤血流动力学和评估前列腺癌过渡区病变的大小依赖性。
{"title":"Quantitative analysis of dynamic-contrast MRI for the assessment of prostate cancer in the transition zone.","authors":"Mariko Doai, Tamaki Kondo, Yuka Nishino, Ippei Chikazawa, Sohsuke Yamada, Keiya Hirata, Katsuhito Miyazawa","doi":"10.1177/03915603251414596","DOIUrl":"https://doi.org/10.1177/03915603251414596","url":null,"abstract":"<p><strong>Purpose: </strong>Differentiating prostate cancer (PCa) in the transition zone (TZ) from benign prostate hyperplasia based on MRI findings has often been challenging. This study aims to evaluate the utility of a quantitative analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using time-resolved angiography with stochastic trajectories‒volumetric interpolated breath-hold examination (TWIST-VIBE) in cases of PCa in the TZ.</p><p><strong>Methods: </strong>In this retrospective study, we examined the biopsy findings of 23 patients with elevated prostate-specific antigen (PSA) levels (>4 ng/mL) who underwent DCE-MRI using TWIST-VIBE. The parameters analyzed included K<sup>trans</sup> (the transfer constant), K<sup>ep</sup> (the reflux constant), Ve (the extravascular extracellular volume fraction), and the initial area under the curve on the Tissue 4D platform (Siemens).</p><p><strong>Results: </strong>The quantitative analysis revealed no significant differences in any of the examined parameters between positive and negative PCa in the TZ. Additionally, there were no significant differences among the histological grades of PCa in the TZ.</p><p><strong>Conclusion: </strong>A quantitative analysis of findings obtained by DCE-MRI using TWIST-VIBE did not yield statistically significant results for differentiating the status of PCa in the TZ. However, DCE-MRI using TWIST-VIBE, an ultrafast DCE-MRI technique, may be useful for evaluating tumor hemodynamics and assessing the size dependence of prostate cancer lesions in the transition zone.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251414596"},"PeriodicalIF":0.7,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146053925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
No screening, no life: Perspectives from a sociodemographic characterization of prostate cancer patients. 没有筛查,就没有生命:从前列腺癌患者的社会人口学特征来看。
IF 0.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-12 DOI: 10.1177/03915603251412607
Lucas J Cortés, Germán Olaya, José S Cortés, Juan I Caicedo, Jorge A Flórez

Background: Prostate cancer is the most common solid neoplasm in men, with an increasing incidence. This study describes clinical and sociodemographic features and PSA levels, and evaluate their associations with stage, risk categories, metastasis, and mortality in a public tertiary hospital in southern Colombia.

Methodology: The present retrospective cohort study included 590 patients diagnosed with prostate cancer between 2020 and 2023. Sociodemographic and clinical variables, PSA levels, pathological characteristics and risk scales were analyzed. Patients were categorized into two groups: living (n = 429) and deceased by prostate cancer (n = 109), and other causes (n = 44). Statistical analyses were performed to determine associations with mortality and presence of metastasis.

Results: PSA screening was more frequent among survivors (66.9%, n = 287) than among deceased (22.0%, n = 24; p < 0.001). Median PSA at diagnosis was higher in those who died (123 vs 16 ng/mL; p < 0.001). PSA > 100 ng/mL was associated with ~50% probability of metastatic disease, rising to >95% for PSA > 323 ng/mL. High-risk D'Amico classification was strongly associated with metastasis (RR 6.67) and mortality (OR 14.24, p < 0.001). Bone pain was the predominant presenting symptom in the deceased group (76.1%, n = 83) and showed a strong association with metastasis (RR 8.146).

Conclusions: PSA screening was strongly associated with improved survival outcomes. Elevated PSA levels, high risk D'Amico classification and the presence of bone pain were important predictors of metastasis and mortality. The need to strengthen early detection in our population is evident, given the high percentage of patients presenting at advanced stages.

背景:前列腺癌是男性最常见的实体肿瘤,发病率呈上升趋势。本研究描述了哥伦比亚南部一家公立三级医院的临床和社会人口学特征和PSA水平,并评估了它们与分期、风险类别、转移和死亡率的关系。方法:本回顾性队列研究纳入了2020年至2023年间诊断为前列腺癌的590例患者。分析社会人口学和临床变量、PSA水平、病理特征和风险量表。患者分为两组:存活(n = 429)和死于前列腺癌(n = 109),以及其他原因(n = 44)。进行统计分析以确定与死亡率和转移的关系。结果:PSA筛查在幸存者中(66.9%,n = 287)比在死者中(22.0%,n = 24)更频繁;PSA 100 ng/mL与转移性疾病的概率相关约50%,PSA 323 ng/mL与转移性疾病的概率相关约95%。高危D'Amico分类与转移(RR = 6.67)和死亡率(OR = 14.24, p = 83)密切相关,与转移(RR = 8.146)密切相关。结论:PSA筛查与改善生存结果密切相关。PSA水平升高、高风险D'Amico分类和骨痛的存在是转移和死亡的重要预测因素。鉴于晚期患者的比例很高,加强我国人口早期检测的必要性是显而易见的。
{"title":"No screening, no life: Perspectives from a sociodemographic characterization of prostate cancer patients.","authors":"Lucas J Cortés, Germán Olaya, José S Cortés, Juan I Caicedo, Jorge A Flórez","doi":"10.1177/03915603251412607","DOIUrl":"https://doi.org/10.1177/03915603251412607","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is the most common solid neoplasm in men, with an increasing incidence. This study describes clinical and sociodemographic features and PSA levels, and evaluate their associations with stage, risk categories, metastasis, and mortality in a public tertiary hospital in southern Colombia.</p><p><strong>Methodology: </strong>The present retrospective cohort study included 590 patients diagnosed with prostate cancer between 2020 and 2023. Sociodemographic and clinical variables, PSA levels, pathological characteristics and risk scales were analyzed. Patients were categorized into two groups: living (<i>n</i> = 429) and deceased by prostate cancer (<i>n</i> = 109), and other causes (<i>n</i> = 44). Statistical analyses were performed to determine associations with mortality and presence of metastasis.</p><p><strong>Results: </strong>PSA screening was more frequent among survivors (66.9%, <i>n</i> = 287) than among deceased (22.0%, <i>n</i> = 24; <i>p</i> < 0.001). Median PSA at diagnosis was higher in those who died (123 vs 16 ng/mL; <i>p</i> < 0.001). PSA > 100 ng/mL was associated with ~50% probability of metastatic disease, rising to >95% for PSA > 323 ng/mL. High-risk D'Amico classification was strongly associated with metastasis (RR 6.67) and mortality (OR 14.24, <i>p</i> < 0.001). Bone pain was the predominant presenting symptom in the deceased group (76.1%, <i>n</i> = 83) and showed a strong association with metastasis (RR 8.146).</p><p><strong>Conclusions: </strong>PSA screening was strongly associated with improved survival outcomes. Elevated PSA levels, high risk D'Amico classification and the presence of bone pain were important predictors of metastasis and mortality. The need to strengthen early detection in our population is evident, given the high percentage of patients presenting at advanced stages.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251412607"},"PeriodicalIF":0.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transitional cell carcinoma in distal urethra after previous excision of HPV related condyloma: Is there a link between human papilloma virus (HPV) and transitional cell carcinoma (TCC)? HPV相关尖锐湿疣切除术后尿道远端移行细胞癌:人乳头瘤病毒(HPV)和移行细胞癌(TCC)之间是否存在联系?
IF 0.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-06 DOI: 10.1177/03915603251412604
Aldo Franco De Rose, Tommaso Saccucci, Benedetta Col, Fabrizio Gallo, Maurizio Chiaramondia, Guglielmo Mantica

Introduction: We aim to present a peculiar case of a patient we treated, who underwent surgical excision of what at first were HPV-related condylomas of the urethral meatus. The second time he underwent surgical excision of what seemed a recurrence the histology showed a low grade noninvasive papillary urothelial carcinoma.

Case description: A 56-year-old man who underwent surgical excision of multiple lesions of the gland and distal urethra in April 2023; the histological examination of the neoformations in distal urethra confirmed the presence of condyloma acuminatum. He experienced a recurrence of distal urethral lesion; therefore, he underwent to a new surgical excision in September 2023 and this time the histological examination showed a transitional cell carcinoma.

Conclusion: There is still no clear evidence of the link between HPV infection and TCC, however attention must be placed in order to enhance awareness on HPV infection prevention and on TCC screening for patient with other HPV infection related diseases.

简介:我们的目的是提出一个特殊的情况下,我们治疗的病人,谁接受手术切除什么在最初是hpv相关尖锐湿疣尿道道。第二次手术切除似乎是复发,组织学显示为低级别非侵袭性乳头状尿路上皮癌。病例描述:一名56岁男性,于2023年4月手术切除了腺体和尿道远端多发病变;尿道远端新生组织的组织学检查证实了尖锐湿疣的存在。他经历了尿道远端病变复发;因此,他于2023年9月接受了新的手术切除,这次的组织学检查显示为移行细胞癌。结论:目前仍没有明确的证据表明HPV感染与TCC之间存在联系,但应引起重视,以提高对HPV感染的预防意识,并对其他HPV感染相关疾病患者进行TCC筛查。
{"title":"Transitional cell carcinoma in distal urethra after previous excision of HPV related condyloma: Is there a link between human papilloma virus (HPV) and transitional cell carcinoma (TCC)?","authors":"Aldo Franco De Rose, Tommaso Saccucci, Benedetta Col, Fabrizio Gallo, Maurizio Chiaramondia, Guglielmo Mantica","doi":"10.1177/03915603251412604","DOIUrl":"https://doi.org/10.1177/03915603251412604","url":null,"abstract":"<p><strong>Introduction: </strong>We aim to present a peculiar case of a patient we treated, who underwent surgical excision of what at first were HPV-related condylomas of the urethral meatus. The second time he underwent surgical excision of what seemed a recurrence the histology showed a low grade noninvasive papillary urothelial carcinoma.</p><p><strong>Case description: </strong>A 56-year-old man who underwent surgical excision of multiple lesions of the gland and distal urethra in April 2023; the histological examination of the neoformations in distal urethra confirmed the presence of condyloma acuminatum. He experienced a recurrence of distal urethral lesion; therefore, he underwent to a new surgical excision in September 2023 and this time the histological examination showed a transitional cell carcinoma.</p><p><strong>Conclusion: </strong>There is still no clear evidence of the link between HPV infection and TCC, however attention must be placed in order to enhance awareness on HPV infection prevention and on TCC screening for patient with other HPV infection related diseases.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251412604"},"PeriodicalIF":0.7,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostate health supporting by a novel nutraceutical compound with antioxidant property: Results from a pilot study. 一种具有抗氧化特性的新型营养化合物对前列腺健康的支持:一项初步研究的结果。
IF 0.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-05 DOI: 10.1177/03915603251408298
Claudio Marino, Marco Magliocchetti, Dario Di Lieto, Erika Cione, Cristina Vocca, Tommaso Ceccato, Simone Botti, Fabrizio Palumbo, Luca Gallelli, Tommaso Cai

In recent years, healthcare strategies have increasingly emphasized a holistic and comprehensive approach in patient management that extends beyond the treatment of isolated physical symptoms. In this context, the use of nutraceuticals has gained interest as a complementary approach, particularly in managing chronic conditions and age-related disorders, such as lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH). A new dietary supplement, contains a blend of bio-active compounds (Drolessano®)-including lycopene, sulforaphane, silymarin, glutathione, escine, tryptophan, and green tea extract-has been introduced in Italian pharmacopeia as food supplements in urological and andrological diseases. Here, we aim to assess the effects of Drolessano® on serum prostate-specific antigen (PSA) levels and urinary symptoms in individuals with BPH. Fifty-five men presenting with elevated PSA values and mild lower urinary tract symptoms (International Prostate Symptom Score [IPSS] < 7) were recruited in this pilot study. All enrolled patients underwent Drolessano® one tablet daily for 6 months. PSA concentrations and IPSS scores were recorded at baseline (T0), at 3 months (T1), and at the end of the treatment period (T2). Data at the follow-up has been compared with those at baseline. Patients enrolled experienced a statistical significance average PSA declined from 4.8 to 3.7 ng/mL (p < 0.003), as well as in improvement of quality of life, tested by patient reported outcomes. The supplement was generally well tolerated, and no serious adverse effects were reported during the study period. These preliminary data suggest that Drolessano® may offer a supportive benefit in the management of BPH, particularly with respect to reducing PSA levels and improvement quality of life. Otherwise, controlled trials with larger sample sizes are needed to substantiate these findings and to better understand the underlying mechanisms of action.

近年来,医疗保健战略越来越强调在患者管理中采用整体和综合的方法,而不仅仅是治疗孤立的身体症状。在这种情况下,保健品作为一种补充方法的使用引起了人们的兴趣,特别是在治疗慢性疾病和年龄相关疾病方面,如良性前列腺增生(BPH)引起的下尿路症状(LUTS)。一种新的膳食补充剂,含有混合的生物活性化合物(Drolessano®)-包括番茄红素,萝卜硫素,水飞蓟素,谷胱甘肽,叶青素,色氨酸和绿茶提取物-已被引入意大利药典作为泌尿和男性疾病的食品补充剂。在这里,我们的目的是评估Drolessano®对BPH患者血清前列腺特异性抗原(PSA)水平和泌尿系统症状的影响。55名男性表现为PSA值升高和轻度下尿路症状(国际前列腺症状评分[IPSS]®),每天一片,持续6个月。在基线(T0)、3个月(T1)和治疗期结束(T2)时记录PSA浓度和IPSS评分。随访时的数据与基线时的数据进行了比较。纳入的患者平均PSA从4.8降至3.7 ng/mL (p®),具有统计学意义,可能对BPH的管理具有支持作用,特别是在降低PSA水平和改善生活质量方面。否则,需要更大样本量的对照试验来证实这些发现,并更好地了解潜在的作用机制。
{"title":"Prostate health supporting by a novel nutraceutical compound with antioxidant property: Results from a pilot study.","authors":"Claudio Marino, Marco Magliocchetti, Dario Di Lieto, Erika Cione, Cristina Vocca, Tommaso Ceccato, Simone Botti, Fabrizio Palumbo, Luca Gallelli, Tommaso Cai","doi":"10.1177/03915603251408298","DOIUrl":"https://doi.org/10.1177/03915603251408298","url":null,"abstract":"<p><p>In recent years, healthcare strategies have increasingly emphasized a holistic and comprehensive approach in patient management that extends beyond the treatment of isolated physical symptoms. In this context, the use of nutraceuticals has gained interest as a complementary approach, particularly in managing chronic conditions and age-related disorders, such as lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH). A new dietary supplement, contains a blend of bio-active compounds (Drolessano<sup>®</sup>)-including lycopene, sulforaphane, silymarin, glutathione, escine, tryptophan, and green tea extract-has been introduced in Italian pharmacopeia as food supplements in urological and andrological diseases. Here, we aim to assess the effects of Drolessano<sup>®</sup> on serum prostate-specific antigen (PSA) levels and urinary symptoms in individuals with BPH. Fifty-five men presenting with elevated PSA values and mild lower urinary tract symptoms (International Prostate Symptom Score [IPSS] < 7) were recruited in this pilot study. All enrolled patients underwent Drolessano<sup>®</sup> one tablet daily for 6 months. PSA concentrations and IPSS scores were recorded at baseline (T0), at 3 months (T1), and at the end of the treatment period (T2). Data at the follow-up has been compared with those at baseline. Patients enrolled experienced a statistical significance average PSA declined from 4.8 to 3.7 ng/mL (<i>p</i> < 0.003), as well as in improvement of quality of life, tested by patient reported outcomes. The supplement was generally well tolerated, and no serious adverse effects were reported during the study period. These preliminary data suggest that Drolessano<sup>®</sup> may offer a supportive benefit in the management of BPH, particularly with respect to reducing PSA levels and improvement quality of life. Otherwise, controlled trials with larger sample sizes are needed to substantiate these findings and to better understand the underlying mechanisms of action.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251408298"},"PeriodicalIF":0.7,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of ureteric jet in kidney transplant recipient. 肾移植受者输尿管射流的研究。
IF 0.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-05 DOI: 10.1177/03915603251410689
Sunil Kumar Das, VedVyas Mishra, Elisha Paikray, Bipin Bihari Pradhan

Introduction: An intact vescio-ureteric junction (VUJ) complex is necessary to maintain its normal physiological function. A ureteric jet is produced when urine is vigorously propelled from the VUJ into the urinary bladder. The transplanted ureter lacks a normal VUJ but maintains its intrinsic peristaltic activity. this study was conducted to compare prospectively between the ureteric jet parameters in voluntary kidney donors by Doppler ultrasound of the same with patients who underwent ureteric re-implantation during a kidney transplantation procedure.

Methods: There were a total of 44 participants in the study. The outcome measurements were taken of the anteriorposterior diameter of the renal pelvis (RP-APD), the resistive index of the renal artery (RA-Ri), and ureteric jet parameters- the jet's maximum velocity, pattern, initial slope, direction, and duration. The patterns were of the following types - triphasic, biphasic, polyphasic, square, continuous, and monophasic.

Result: The biphasic and monophasic jet pattern was most common in the donor and recipient groups, respectively.

Conclusion: The Doppler waveform observed in transplanted ureters significantly differs from that seen in healthy voluntary kidney donors. This observation lends support to the theory that the native VUJ functions as a sphincter.

完整的膀胱输尿管连接(VUJ)复合体是维持其正常生理功能所必需的。当尿液从VUJ被大力推进到膀胱时,就会产生输尿管射流。移植输尿管缺乏正常的输尿管腔,但仍保持其固有的蠕动活动。本研究旨在通过多普勒超声前瞻性比较自愿肾供者与肾移植过程中输尿管再植入患者输尿管射流参数。方法:共44名受试者。结果测量了肾盂前后径(RP-APD)、肾动脉阻力指数(RA-Ri)和输尿管射流参数——射流的最大速度、模式、初始斜率、方向和持续时间。其模式有:三相、双相、多相、方形、连续和单相。结果:供体组和受体组分别以双相和单相喷流模式最常见。结论:输尿管移植的多普勒波形与健康自愿供肾者有显著差异。这一观察结果支持了原生VUJ作为括约肌的理论。
{"title":"Study of ureteric jet in kidney transplant recipient.","authors":"Sunil Kumar Das, VedVyas Mishra, Elisha Paikray, Bipin Bihari Pradhan","doi":"10.1177/03915603251410689","DOIUrl":"https://doi.org/10.1177/03915603251410689","url":null,"abstract":"<p><strong>Introduction: </strong>An intact vescio-ureteric junction (VUJ) complex is necessary to maintain its normal physiological function. A ureteric jet is produced when urine is vigorously propelled from the VUJ into the urinary bladder. The transplanted ureter lacks a normal VUJ but maintains its intrinsic peristaltic activity. this study was conducted to compare prospectively between the ureteric jet parameters in voluntary kidney donors by Doppler ultrasound of the same with patients who underwent ureteric re-implantation during a kidney transplantation procedure.</p><p><strong>Methods: </strong>There were a total of 44 participants in the study. The outcome measurements were taken of the anteriorposterior diameter of the renal pelvis (RP-APD), the resistive index of the renal artery (RA-Ri), and ureteric jet parameters- the jet's maximum velocity, pattern, initial slope, direction, and duration. The patterns were of the following types - triphasic, biphasic, polyphasic, square, continuous, and monophasic.</p><p><strong>Result: </strong>The biphasic and monophasic jet pattern was most common in the donor and recipient groups, respectively.</p><p><strong>Conclusion: </strong>The Doppler waveform observed in transplanted ureters significantly differs from that seen in healthy voluntary kidney donors. This observation lends support to the theory that the native VUJ functions as a sphincter.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251410689"},"PeriodicalIF":0.7,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence-assisted uroflowmetry and automated evaluation of lower urinary system symptoms. 人工智能辅助尿流测定和下泌尿系统症状的自动评估。
IF 0.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-12-27 DOI: 10.1177/03915603251406813
Hakan Şığva, Arif Mehmet Duran, Berat Deniz, Kadir Körpe, Mehmet Sevim

Purpose: This study aimed to develop and validate an AI-assisted framework for the automated evaluation of uroflowmetry data in patients presenting with lower urinary tract symptoms. The primary goal was to overcome the limitations of traditional manual interpretations by leveraging advanced machine learning techniques to achieve higher diagnostic accuracy, objectivity, and clinical applicability in urological assessments.

Materials and methods: A retrospective analysis was conducted using a large, de-identified dataset comprising uroflowmetry recordings, patient-reported symptom scores, and comprehensive demographic data. The data underwent rigorous preprocessing-including noise reduction, baseline correction, normalization, and feature extraction-with key parameters such as peak flow rate, voided volume, average flow rate, and voiding time being analyzed. Multiple machine learning models-including a deep neural network, support vector machine, and random forest classifier-were developed and validated through cross-validation and extensive statistical testing. Performance metrics such as accuracy, sensitivity, specificity, and area under the ROC curve (AUC-ROC) were calculated, while multivariate regression analyses were performed to explore the relationships between uroflowmetry parameters and symptom severity.

Results: The AI framework, particularly the deep neural network model, exhibited outstanding diagnostic performance with an accuracy of 92.5%, sensitivity of 90.0%, specificity of 94.0%, and an AUC-ROC of 0.96. Statistical analyses demonstrated significant correlations between key uroflowmetry parameters and clinical symptoms, with lower peak flow rates showing a strong association with increased symptom severity (p < 0.001). These findings confirm that the integration of multi-dimensional data through AI significantly enhances the objectivity and precision of urinary function evaluation compared to conventional methods.

Conclusion: The study successfully established an AI-assisted diagnostic framework that markedly improves the automated evaluation of uroflowmetry data and lower urinary tract symptoms. This innovative approach offers a robust alternative to traditional diagnostic practices by reducing subjectivity and enhancing diagnostic accuracy, thereby paving the way for more personalized and effective management of urinary disorders.

目的:本研究旨在开发和验证人工智能辅助框架,用于自动评估出现下尿路症状的患者的尿流测量数据。主要目标是通过利用先进的机器学习技术来克服传统人工解释的局限性,从而在泌尿科评估中实现更高的诊断准确性、客观性和临床适用性。材料和方法:使用一个大型的、去识别的数据集进行回顾性分析,该数据集包括尿流仪记录、患者报告的症状评分和综合的人口统计数据。数据经过了严格的预处理,包括降噪、基线校正、归一化和特征提取,并分析了峰值流量、空泡体积、平均流量和空泡时间等关键参数。多个机器学习模型——包括深度神经网络、支持向量机和随机森林分类器——通过交叉验证和广泛的统计测试进行了开发和验证。计算准确性、敏感性、特异性和ROC曲线下面积(AUC-ROC)等性能指标,并进行多变量回归分析,探讨尿流仪参数与症状严重程度之间的关系。结果:人工智能框架特别是深度神经网络模型的诊断准确率为92.5%,灵敏度为90.0%,特异性为94.0%,AUC-ROC为0.96。统计分析表明,尿流测定关键参数与临床症状之间存在显著相关性,较低的峰值流量与症状严重程度的增加有很强的相关性(p)。结论:该研究成功建立了一个人工智能辅助诊断框架,显著提高了尿流测定数据和下尿路症状的自动评估。这种创新的方法通过减少主观性和提高诊断准确性,为传统诊断实践提供了强有力的替代方案,从而为更加个性化和有效的泌尿系统疾病管理铺平了道路。
{"title":"Artificial intelligence-assisted uroflowmetry and automated evaluation of lower urinary system symptoms.","authors":"Hakan Şığva, Arif Mehmet Duran, Berat Deniz, Kadir Körpe, Mehmet Sevim","doi":"10.1177/03915603251406813","DOIUrl":"https://doi.org/10.1177/03915603251406813","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to develop and validate an AI-assisted framework for the automated evaluation of uroflowmetry data in patients presenting with lower urinary tract symptoms. The primary goal was to overcome the limitations of traditional manual interpretations by leveraging advanced machine learning techniques to achieve higher diagnostic accuracy, objectivity, and clinical applicability in urological assessments.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted using a large, de-identified dataset comprising uroflowmetry recordings, patient-reported symptom scores, and comprehensive demographic data. The data underwent rigorous preprocessing-including noise reduction, baseline correction, normalization, and feature extraction-with key parameters such as peak flow rate, voided volume, average flow rate, and voiding time being analyzed. Multiple machine learning models-including a deep neural network, support vector machine, and random forest classifier-were developed and validated through cross-validation and extensive statistical testing. Performance metrics such as accuracy, sensitivity, specificity, and area under the ROC curve (AUC-ROC) were calculated, while multivariate regression analyses were performed to explore the relationships between uroflowmetry parameters and symptom severity.</p><p><strong>Results: </strong>The AI framework, particularly the deep neural network model, exhibited outstanding diagnostic performance with an accuracy of 92.5%, sensitivity of 90.0%, specificity of 94.0%, and an AUC-ROC of 0.96. Statistical analyses demonstrated significant correlations between key uroflowmetry parameters and clinical symptoms, with lower peak flow rates showing a strong association with increased symptom severity (<i>p</i> < 0.001). These findings confirm that the integration of multi-dimensional data through AI significantly enhances the objectivity and precision of urinary function evaluation compared to conventional methods.</p><p><strong>Conclusion: </strong>The study successfully established an AI-assisted diagnostic framework that markedly improves the automated evaluation of uroflowmetry data and lower urinary tract symptoms. This innovative approach offers a robust alternative to traditional diagnostic practices by reducing subjectivity and enhancing diagnostic accuracy, thereby paving the way for more personalized and effective management of urinary disorders.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251406813"},"PeriodicalIF":0.7,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tailoring robotic-assisted partial nephrectomy: Should a retro- or transperitoneal approach be adapted based on tumor location, rather than surgeon's preference? 定制机器人辅助部分肾切除术:是否应该根据肿瘤位置,而不是外科医生的偏好,采用逆行或经腹膜入路?
IF 0.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-12-27 DOI: 10.1177/03915603251407024
Valeria Feliciangeli, Nunzia Abbate, Luca Orecchia, Giuseppe Farullo, Anastasios Asimakopoulos, Enrico Finazzi Agrò, Simone Albisinni

Robotic-Assisted Partial Nephrectomy (RAPN) can be performed via a transperitoneal (t-RAPN) or retroperitoneal (r-RAPN) approach. Despite the retroperitoneal route being potentially more suitable for posterior renal tumors, most surgeons prefer the transperitoneal access due to greater familiarity. This study evaluated perioperative and functional outcomes of r-RAPN versus t-RAPN for posterior renal masses performed by a surgeon without prior retroperitoneal experience. We retrospectively analyzed patients undergoing RAPN for posterior renal tumors between September 2023 and April 2025. Patient and tumor characteristics, operative time (OT), warm ischemia time (WIT), ΔeGFR, length of stay (LOS), complications, and Trifecta rate were compared. Trifecta was defined as WIT < 25 min, negative margins, and absence of Clavien-Dindo ⩾ III complications. Twenty patients were included: eight underwent t-RAPN and 12 r-RAPN. Baseline features were comparable. r-RAPN showed significantly shorter OT (125 ± 29 min vs 168 ± 37 min, p = 0.01), time on console (72 min vs 110 min, p = 0.01), and WIT (12 min vs 18 min, p = 0.048). Trifecta was achieved in all cases. Multivariate analysis identified surgical approach as the only independent predictor of console time (p = 0.024), with r-RAPN reducing it by 39 min. In conclusion, r-RAPN is feasible and safe even without prior retroperitoneal experience, offering comparable outcomes to t-RAPN with shorter operative times.

机器人辅助部分肾切除术(RAPN)可以通过经腹膜(t-RAPN)或腹膜后(r-RAPN)入路进行。尽管腹膜后途径可能更适合后侧肾肿瘤,但由于更熟悉,大多数外科医生更倾向于经腹膜途径。这项研究评估了由没有腹膜后手术经验的外科医生进行后肾肿块手术时r-RAPN与t-RAPN的围手术期和功能结果。我们回顾性分析了2023年9月至2025年4月期间接受RAPN治疗后肾肿瘤的患者。比较患者及肿瘤特征、手术时间(OT)、热缺血时间(WIT)、ΔeGFR、住院时间(LOS)、并发症及三氟替尼率。triecta的定义为WIT (p = 0.01),控制台时间(72分钟vs 110分钟,p = 0.01)和WIT(12分钟vs 18分钟,p = 0.048)。所有病例均达到三连效。多变量分析发现手术入路是唯一的独立预测因子(p = 0.024), r-RAPN使其减少39分钟。总之,r-RAPN是可行和安全的,即使没有先前的腹膜后经验,其结果与t-RAPN相当,手术时间更短。
{"title":"Tailoring robotic-assisted partial nephrectomy: Should a retro- or transperitoneal approach be adapted based on tumor location, rather than surgeon's preference?","authors":"Valeria Feliciangeli, Nunzia Abbate, Luca Orecchia, Giuseppe Farullo, Anastasios Asimakopoulos, Enrico Finazzi Agrò, Simone Albisinni","doi":"10.1177/03915603251407024","DOIUrl":"https://doi.org/10.1177/03915603251407024","url":null,"abstract":"<p><p>Robotic-Assisted Partial Nephrectomy (RAPN) can be performed via a transperitoneal (t-RAPN) or retroperitoneal (r-RAPN) approach. Despite the retroperitoneal route being potentially more suitable for posterior renal tumors, most surgeons prefer the transperitoneal access due to greater familiarity. This study evaluated perioperative and functional outcomes of r-RAPN versus t-RAPN for posterior renal masses performed by a surgeon without prior retroperitoneal experience. We retrospectively analyzed patients undergoing RAPN for posterior renal tumors between September 2023 and April 2025. Patient and tumor characteristics, operative time (OT), warm ischemia time (WIT), ΔeGFR, length of stay (LOS), complications, and Trifecta rate were compared. Trifecta was defined as WIT < 25 min, negative margins, and absence of Clavien-Dindo ⩾ III complications. Twenty patients were included: eight underwent t-RAPN and 12 r-RAPN. Baseline features were comparable. r-RAPN showed significantly shorter OT (125 ± 29 min vs 168 ± 37 min, <i>p</i> = 0.01), time on console (72 min vs 110 min, <i>p</i> = 0.01), and WIT (12 min vs 18 min, <i>p</i> = 0.048). Trifecta was achieved in all cases. Multivariate analysis identified surgical approach as the only independent predictor of console time (<i>p</i> = 0.024), with r-RAPN reducing it by 39 min. In conclusion, r-RAPN is feasible and safe even without prior retroperitoneal experience, offering comparable outcomes to t-RAPN with shorter operative times.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251407024"},"PeriodicalIF":0.7,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Twenty-four months failure rate and functional outcomes comparison after implantable nitinol device (iTIND) and prostatic urethral lift (Urolift): real world multicenter study. 植入式镍钛诺器械(iTIND)和前列腺尿道提升术(Urolift)后24个月的失败率和功能结果比较:真实世界的多中心研究。
IF 0.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-12-27 DOI: 10.1177/03915603251406809
Alberto Olivero, Sabrina De Cillis, Daniele Amparore, Sofia Giudici, Carlo Buratto, Valerio Cellini, Alberto Piana, Federico Piramide, Alberto Quarà, Cristian Fiori, Erika Palagonia, Paolo Dell'Oglio, Stefano Tappero, Aldo Massimo Bocciardi, Alberto Caviglia, Antonio Galfano, Bhaskar K Somani, Amelia Pietropaolo, Francesco Porpiglia, Silvia Secco

Background: In recent years, there has been a growing trend toward minimally-invasive techniques (MISTs) in men presenting symptomatic lower urinary tract symptoms (LUTS). However, direct comparisons between techniques are rare. This work compares 2-year functional outcomes and failure rates after implantable nitinol device (iTIND) and prostatic Urethral lift (Urolift).

Methods: Data of patients presenting with LUTS with an International Prostatic Symptom Score (IPSS) ⩾10, Qmax < 12 mL/s, and prostate volume < 70 mL were obtained retrospectively from two different referral centers' databases. Patients with neurogenic bladder, sphincter abnormalities, urethral strictures, post-void residual (PVR) volume > 250 mL, urinary bladder stones, and active urinary tract infections were excluded from the study. Treatment failure was defined as the need for surgical retreatment for LUTS or ejaculatory dysfunction. Postoperative uroflowmetry, PVR, IPSS, ejaculatory function, and retreatment rate were collected at 24 months follow-up.

Results: A total of 134 cases were collected. iTIND was used in 92 (68.7%) patients and Urolift in 42 (31.3%). Baseline characteristics were similar in both groups; however, Urolift patients were younger, with more significant prostate volumes and median lobe enlargement. No patients developed ejaculatory dysfunctions after the treatment, and the retreatment rate was similar in the two groups (13% vs 11.9% p = 0.8). Urolift demonstrated a shorter length of stay. Uroflowmetry, PVR volume, and symptom scores improved in both groups; iTIND cases showed significantly better symptom score reduction.

Conclusions: The 24-month failure rate was similar for iTIND and Urolift. Urolift reported a shorter hospitalization. Uroflowmetry and PVR results were comparable in both groups. iTIND cases showed slightly superior improvements in symptom scores; however, the clinical significance of this finding must be confirmed by further studies in correlation with prostate volume and median lobe shape.

背景:近年来,出现下尿路症状(LUTS)的男性越来越倾向于采用微创技术(mist)。然而,技术之间的直接比较很少。本研究比较了植入式镍钛诺装置(iTIND)和前列腺尿道提升(Urolift)术后2年的功能结局和失败率。方法:国际前列腺症状评分(IPSS)小于10,Qmax 250 mL,膀胱结石和活动性尿路感染的LUTS患者的数据被排除在研究之外。治疗失败被定义为需要手术治疗LUTS或射精功能障碍。随访24个月,收集术后尿流测量、PVR、IPSS、射精功能、复治率。结果:共收集病例134例。92例(68.7%)患者使用iTIND, 42例(31.3%)患者使用Urolift。两组的基线特征相似;然而,Urolift患者更年轻,前列腺体积和正中叶增大更明显。治疗后无患者出现射精功能障碍,两组再治疗率相似(13% vs 11.9% p = 0.8)。Urolift的停留时间较短。两组患者尿流测量、PVR容积和症状评分均有改善;iTIND病例表现出明显更好的症状评分降低。结论:iTIND和Urolift的24个月失败率相似。Urolift报告住院时间较短。两组尿流仪和PVR结果具有可比性。iTIND病例的症状评分略有改善;然而,这一发现的临床意义必须通过进一步研究前列腺体积和正中叶形状的相关性来证实。
{"title":"Twenty-four months failure rate and functional outcomes comparison after implantable nitinol device (iTIND) and prostatic urethral lift (Urolift): real world multicenter study.","authors":"Alberto Olivero, Sabrina De Cillis, Daniele Amparore, Sofia Giudici, Carlo Buratto, Valerio Cellini, Alberto Piana, Federico Piramide, Alberto Quarà, Cristian Fiori, Erika Palagonia, Paolo Dell'Oglio, Stefano Tappero, Aldo Massimo Bocciardi, Alberto Caviglia, Antonio Galfano, Bhaskar K Somani, Amelia Pietropaolo, Francesco Porpiglia, Silvia Secco","doi":"10.1177/03915603251406809","DOIUrl":"https://doi.org/10.1177/03915603251406809","url":null,"abstract":"<p><strong>Background: </strong>In recent years, there has been a growing trend toward minimally-invasive techniques (MISTs) in men presenting symptomatic lower urinary tract symptoms (LUTS). However, direct comparisons between techniques are rare. This work compares 2-year functional outcomes and failure rates after implantable nitinol device (iTIND) and prostatic Urethral lift (Urolift).</p><p><strong>Methods: </strong>Data of patients presenting with LUTS with an International Prostatic Symptom Score (IPSS) ⩾10, <i>Q</i>max < 12 mL/s, and prostate volume < 70 mL were obtained retrospectively from two different referral centers' databases. Patients with neurogenic bladder, sphincter abnormalities, urethral strictures, post-void residual (PVR) volume > 250 mL, urinary bladder stones, and active urinary tract infections were excluded from the study. Treatment failure was defined as the need for surgical retreatment for LUTS or ejaculatory dysfunction. Postoperative uroflowmetry, PVR, IPSS, ejaculatory function, and retreatment rate were collected at 24 months follow-up.</p><p><strong>Results: </strong>A total of 134 cases were collected. iTIND was used in 92 (68.7%) patients and Urolift in 42 (31.3%). Baseline characteristics were similar in both groups; however, Urolift patients were younger, with more significant prostate volumes and median lobe enlargement. No patients developed ejaculatory dysfunctions after the treatment, and the retreatment rate was similar in the two groups (13% vs 11.9% <i>p</i> = 0.8). Urolift demonstrated a shorter length of stay. Uroflowmetry, PVR volume, and symptom scores improved in both groups; iTIND cases showed significantly better symptom score reduction.</p><p><strong>Conclusions: </strong>The 24-month failure rate was similar for iTIND and Urolift. Urolift reported a shorter hospitalization. Uroflowmetry and PVR results were comparable in both groups. iTIND cases showed slightly superior improvements in symptom scores; however, the clinical significance of this finding must be confirmed by further studies in correlation with prostate volume and median lobe shape.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251406809"},"PeriodicalIF":0.7,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rezum therapy for management of frail patients with catheter dependent urinary retention due to benign prostate hyperplasia : A 1 year follow up study. Rezum治疗良性前列腺增生引起的导管依赖性尿潴留的虚弱患者:1年随访研究。
IF 0.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-12-06 DOI: 10.1177/03915603251398255
Ahmed Issam Ali, Waseem Tayeb, Suhail A Kalantan, Abdelsalam Abdelfadel, Amr Talaat Azzam, Turky Almouhissen, Basem Othman, Abdullah Albkri, Abdulaziz Mohammed Bakhsh, Adel Moalwi, Ali Abdullah Alqahtani, Mohammed Kasem, Abdulrahim A Mirza, Ali Hassan

Purpose: This study presents a 1-year follow-up for fragile patients with catheter-dependent urinary retention related to benign prostatic hyperplasia (BPH) treated with Rezum therapy.

Materials and methods: All patients participating in this study exhibited catheter-dependent urine retention attributable to benign prostatic hyperplasia, with a mean prostate volume of 65 ± 13.1 ml. The study only included fragile patients with a PRISMA-7 questionnaire score of ⩾3. The study excluded patients with bladder or prostate cancer, ongoing urinary tract inflammation, a history of pelvic irradiation or prostate surgery, neurogenic bladder or urethral stricture. The treatment was carried out under local anesthesia, with the possibility of sedation. Patients were asked to follow up after 1, 2, 9, and 12 months of surgery. Clinical assessments included the IPSS score, bladder scans to determine pre- and post-voiding bladder volume, and an evaluation of the requirement for re-catheterization.

Results: Eighty fragile patients with PRISMA-7 score ⩾3 underwent Rezum treatment for urinary retention due to BPH. Patients were monitored for 1 year after the procedure. Patients' IPSS improved from 14 to 9.5 (p = 0.02), while post-void residual urine decreased from 50 mL to 12 mL (p < 0.001). Prostate volume reduced from 60.5 mL to 40.9 mL (p = 0.0003) and PSA levels also dropped, from 3.5 mg/dl to 2.3 ng/ml (p = 0.03).

Conclusion: This study demonstrates that Rezum therapy is a feasible treatment option for frail patients with PRISMA-7 questionnaire score of ⩾3, presented with catheter dependent urinary retention. There were reported positive post-operative outcomes and an improvement in IPSS scores up to one year after surgery.

目的:本研究对接受Rezum治疗的脆弱的导管依赖性尿潴留患者进行了为期1年的随访。材料和方法:所有参与本研究的患者均出现由良性前列腺增生引起的导管依赖性尿潴留,平均前列腺体积为65±13.1 ml。该研究仅包括PRISMA-7问卷评分为大于或等于3的脆弱患者。该研究排除了患有膀胱癌或前列腺癌、持续的尿路炎症、盆腔照射或前列腺手术史、神经源性膀胱或尿道狭窄的患者。治疗在局部麻醉下进行,可能有镇静作用。患者在手术1、2、9和12个月后被要求随访。临床评估包括IPSS评分,膀胱扫描以确定排尿前和排尿后的膀胱容量,以及对重新导尿需求的评估。结果:80名PRISMA-7评分大于或3的脆弱患者因BPH引起的尿潴留接受了Rezum治疗。术后随访1年。患者的IPSS从14改善到9.5 (p = 0.02),空后残尿从50 mL减少到12 mL (p = 0.0003), PSA水平也从3.5 mg/dl下降到2.3 ng/ mL (p = 0.03)。结论:本研究表明,对于PRISMA-7问卷评分大于或3的虚弱患者,出现导管依赖性尿潴留,Rezum治疗是一种可行的治疗选择。据报道,术后结果积极,IPSS评分在术后一年有所改善。
{"title":"Rezum therapy for management of frail patients with catheter dependent urinary retention due to benign prostate hyperplasia : A 1 year follow up study.","authors":"Ahmed Issam Ali, Waseem Tayeb, Suhail A Kalantan, Abdelsalam Abdelfadel, Amr Talaat Azzam, Turky Almouhissen, Basem Othman, Abdullah Albkri, Abdulaziz Mohammed Bakhsh, Adel Moalwi, Ali Abdullah Alqahtani, Mohammed Kasem, Abdulrahim A Mirza, Ali Hassan","doi":"10.1177/03915603251398255","DOIUrl":"https://doi.org/10.1177/03915603251398255","url":null,"abstract":"<p><strong>Purpose: </strong>This study presents a 1-year follow-up for fragile patients with catheter-dependent urinary retention related to benign prostatic hyperplasia (BPH) treated with Rezum therapy.</p><p><strong>Materials and methods: </strong>All patients participating in this study exhibited catheter-dependent urine retention attributable to benign prostatic hyperplasia, with a mean prostate volume of 65 ± 13.1 ml. The study only included fragile patients with a PRISMA-7 questionnaire score of ⩾3. The study excluded patients with bladder or prostate cancer, ongoing urinary tract inflammation, a history of pelvic irradiation or prostate surgery, neurogenic bladder or urethral stricture. The treatment was carried out under local anesthesia, with the possibility of sedation. Patients were asked to follow up after 1, 2, 9, and 12 months of surgery. Clinical assessments included the IPSS score, bladder scans to determine pre- and post-voiding bladder volume, and an evaluation of the requirement for re-catheterization.</p><p><strong>Results: </strong>Eighty fragile patients with PRISMA-7 score ⩾3 underwent Rezum treatment for urinary retention due to BPH. Patients were monitored for 1 year after the procedure. Patients' IPSS improved from 14 to 9.5 (<i>p</i> = 0.02), while post-void residual urine decreased from 50 mL to 12 mL (<i>p</i> < 0.001). Prostate volume reduced from 60.5 mL to 40.9 mL (<i>p</i> = 0.0003) and PSA levels also dropped, from 3.5 mg/dl to 2.3 ng/ml (<i>p</i> = 0.03).</p><p><strong>Conclusion: </strong>This study demonstrates that Rezum therapy is a feasible treatment option for frail patients with PRISMA-7 questionnaire score of ⩾3, presented with catheter dependent urinary retention. There were reported positive post-operative outcomes and an improvement in IPSS scores up to one year after surgery.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251398255"},"PeriodicalIF":0.7,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of urethral stricture score (USS) in predicting intraoperative complexity and postoperative outcome in anterior urethral stricture: An observational study. 评价尿道狭窄评分(USS)在预测前尿道狭窄术中复杂性和术后预后中的作用:一项观察性研究。
IF 0.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-12-06 DOI: 10.1177/03915603251360159
Souvik Chatterjee, Smita Verma, Debansu Sarkar

Introduction: Urethral stricture is common in men with anterior being more common. Number of surgical techniques are there for anterior urethral stricture depending upon location and extent of stricture. To compare one technique with another in terms of complexity, intra-op difficulty and recurrence, no standard scoring system is there. In order to quantify anterior urethral stricture disease, Weigand developed USS (UREThRAL Stricture Score) in 2012. This scoring system was based on preoperative imaging and intraoperative findings. This scoring system has not been accepted worldwide. The aim of this study is to evaluate the USS in predicting intraoperative complexity and postoperative outcome in anterior urethral stricture disease.

Methods: This ambidirectional study included patients operated for anterior urethral stricture in our institute. USS score for each patient was calculated preoperatively. Patients underwent optical internal urethrotomy (OIU), anastomotic urethroplasty or buccal mucosal graft urethroplasty (BMG). Complexity of surgery (in terms of duration of surgery and need of blood transfusion) and postoperative outcome (post op complications and recurrence) was evaluated for association with USS score.

Results: The study included 100 patients. Mean duration of surgery for overall study population was 99.39 ± 55.78 min with strong positive correlation of 0.76 (p-value < 0.001) with USS. Subgroup analysis revealed significant association between USS and postoperative complications (p-value 0.032) and recurrence of stricture (p-value 0.003) in OIU patients. There was also showed that there was significant association between USS and time to recurrence in patients who underwent OIU (p-value 0.007).

Conclusion: Our study validates the USS in predicting complexity of surgery, postoperative complications and recurrence in anterior urethral stricture disease. Higher the USS, more complex is the surgery needed for anterior urethral stricture, more chances of postoperative complications and recurrence of stricture.

尿道狭窄常见于男性,以前尿道狭窄多见。根据狭窄的位置和程度,前尿道狭窄有许多手术技术。为了比较一种技术与另一种技术的复杂性、术中难度和复发性,没有标准的评分系统。为了量化前尿道狭窄疾病,Weigand于2012年开发了USS(尿道狭窄评分)。该评分系统基于术前影像和术中发现。这个评分系统还没有在世界范围内被接受。本研究的目的是评估USS在预测前尿道狭窄疾病的术中复杂性和术后预后方面的作用。方法:本研究纳入我院前尿道狭窄手术患者。术前计算每位患者的USS评分。患者接受光学内尿道切开术(OIU)、吻合口尿道成形术或颊粘膜移植尿道成形术(BMG)。评估手术复杂性(手术持续时间和输血需要)和术后结局(术后并发症和复发)与USS评分的相关性。结果:纳入100例患者。总体研究人群的平均手术时间为99.39±55.78 min,与OIU患者狭窄复发(p值为0.032)呈正相关,p值为0.76 (p值为0.032)。在接受OIU治疗的患者中,USS与复发时间有显著相关性(p值0.007)。结论:本研究验证了USS在预测前尿道狭窄疾病手术复杂性、术后并发症和复发方面的作用。USS越高,前尿道狭窄手术越复杂,术后并发症和狭窄复发的几率越大。
{"title":"Evaluation of urethral stricture score (USS) in predicting intraoperative complexity and postoperative outcome in anterior urethral stricture: An observational study.","authors":"Souvik Chatterjee, Smita Verma, Debansu Sarkar","doi":"10.1177/03915603251360159","DOIUrl":"https://doi.org/10.1177/03915603251360159","url":null,"abstract":"<p><strong>Introduction: </strong>Urethral stricture is common in men with anterior being more common. Number of surgical techniques are there for anterior urethral stricture depending upon location and extent of stricture. To compare one technique with another in terms of complexity, intra-op difficulty and recurrence, no standard scoring system is there. In order to quantify anterior urethral stricture disease, Weigand developed USS (UREThRAL Stricture Score) in 2012. This scoring system was based on preoperative imaging and intraoperative findings. This scoring system has not been accepted worldwide. The aim of this study is to evaluate the USS in predicting intraoperative complexity and postoperative outcome in anterior urethral stricture disease.</p><p><strong>Methods: </strong>This ambidirectional study included patients operated for anterior urethral stricture in our institute. USS score for each patient was calculated preoperatively. Patients underwent optical internal urethrotomy (OIU), anastomotic urethroplasty or buccal mucosal graft urethroplasty (BMG). Complexity of surgery (in terms of duration of surgery and need of blood transfusion) and postoperative outcome (post op complications and recurrence) was evaluated for association with USS score.</p><p><strong>Results: </strong>The study included 100 patients. Mean duration of surgery for overall study population was 99.39 ± 55.78 min with strong positive correlation of 0.76 (<i>p</i>-value < 0.001) with USS. Subgroup analysis revealed significant association between USS and postoperative complications (<i>p</i>-value 0.032) and recurrence of stricture (<i>p</i>-value 0.003) in OIU patients. There was also showed that there was significant association between USS and time to recurrence in patients who underwent OIU (<i>p</i>-value 0.007).</p><p><strong>Conclusion: </strong>Our study validates the USS in predicting complexity of surgery, postoperative complications and recurrence in anterior urethral stricture disease. Higher the USS, more complex is the surgery needed for anterior urethral stricture, more chances of postoperative complications and recurrence of stricture.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251360159"},"PeriodicalIF":0.7,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Urologia Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1